Denali Therapeutics (DNLI) Share-based Compensation (2017 - 2026)
Denali Therapeutics (DNLI) posted quarterly Share-based Compensation of $23.1 million for Q1 2026, down 8.24% year-over-year from $25.2 million in Q1 2025, and down 3.61% quarter-over-quarter from $24.0 million in Q4 2025.
Denali Therapeutics (DNLI) Share-based Compensation (2017 - 2026) Analysis & Trends
Denali Therapeutics (DNLI) has reported Share-based Compensation for 10 consecutive years, with $23.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Share-based Compensation fell 8.24% year-over-year to $23.1 million; the TTM figure through Mar 2026 stood at $97.6 million (down 2.63% YoY), while the FY2025 annual figure was $99.6 million, down 3.15% from the prior year.
- Share-based Compensation declined to $23.1 million in Q1 2026 per DNLI's latest filing, from $24.0 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $28.1 million in Q1 2023 and bottomed at $23.1 million in Q1 2026.
- Historically, Share-based Compensation has averaged $25.5 million across 5 years, with a median of $25.2 million in 2025.
- Annual changes were most pronounced in 2022 — Share-based Compensation climbed 24.33% — and 2025, when it slipped 9.63%.
- Denali Therapeutics' Share-based Compensation stood at $25.2 million in 2022, then climbed by 3.18% to $26.0 million in 2023, then dropped by 3.5% to $25.1 million in 2024, then dropped by 4.49% to $24.0 million in 2025, then declined by 3.61% to $23.1 million in 2026.
- Business Quant data shows DNLI's Share-based Compensation at $23.1 million in Q1 2026, $24.0 million in Q4 2025, and $25.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Denali Therapeutics | 3.90 Bn | 3.90 Bn | 3.51 Mn | 22.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 22.92 Mn |
| Jun 30, 2026 | 22.92 Mn |
| Mar 31, 2026 | 23.09 Mn |
| Mar 31, 2026 | 23.09 Mn |
| Dec 31, 2025 | 23.95 Mn |
| Dec 31, 2025 | 23.95 Mn |
| Sep 30, 2025 | 25.14 Mn |
| Sep 30, 2025 | 25.14 Mn |
| Jun 30, 2025 | 25.39 Mn |
| Jun 30, 2025 | 25.39 Mn |
| Mar 31, 2025 | 25.16 Mn |
| Mar 31, 2025 | 25.16 Mn |
| Dec 31, 2024 | 25.08 Mn |
| Dec 31, 2024 | 25.08 Mn |
| Sep 30, 2024 | 24.86 Mn |
| Sep 30, 2024 | 24.86 Mn |
| Jun 30, 2024 | 25.10 Mn |
| Jun 30, 2024 | 25.10 Mn |
| Mar 31, 2024 | 27.84 Mn |
| Mar 31, 2024 | 27.84 Mn |